Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sarah Cannon Research Institute and AstraZeneca Partner

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Institute and company announce personalized medicine partnership and enhanced strategic clinical development collaboration.

Sarah Cannon Research Institute (SCRI) and AstraZeneca (AZ) announced a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds. Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy.

“Through our research, we know how vital and impactful individualized treatment options are for patients battling this complex disease,” said Dee Anna Smith, chief executive officer of SCRI. “By partnering with AstraZeneca, we are expanding opportunities to accelerate drug development and deliver more targeted therapies to patients who urgently need them.”

Under the agreement, SCRI will work with AstraZeneca to identify potential patients for clinical trials and help explore biomarkers that predict response to specific treatments. In addition, SCRI’s enhanced relationship with AstraZeneca will provide clinical program development leadership, medical expertise and oversight, and operational contract research organization (CRO) trial management for early phase clinical development of multiple oncology compounds.

“Building upon this unique collaboration with SCRI allows us to continue honing our capabilities to deliver high quality research in a timely and cost-effective manner,” said Vice President of Early Clinical Development for AstraZeneca, Professor Andrew Hughes. “Through this cutting-edge program design, we can rapidly and effectively implement clinical trials with greater access to a network of cancer patients for enrollment.”

AstraZeneca is one of the initial participants in SCRI’s molecular profiling program, which is part of Sarah Cannon’s broader personalized medicine initiative across the United States and United Kingdom. SCRI and AstraZeneca originally entered into an agreement to develop novel oncology compounds in 2010.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!